Loading articles...
Giredestrant Improves Breast Cancer Survival Regardless of Menopause
Giredestrant, an oral selective estrogen receptor degrader (SERD), demonstrated improved invasive disease-free survival in early breast cancer.
Tucatinib Extends PFS in HER2-Positive Breast Cancer, No New Safety Signals
Tucatinib demonstrated extended progression-free survival in HER2-positive breast cancer with a consistent safety profile, reinforcing its role.
Breast Cancer in Transgender Individuals: More Research Needed
Current literature on breast cancer in transgender and gender-diverse individuals is limited, highlighting a need for more inclusive research and care strategies.
GLP-1 Agonists: Less Weight Loss, Possible Breast Cancer Survival
GLP-1 receptor agonists, while not primarily indicated for oncology, show potential for survival benefits in breast cancer patients.
Metastatic ILC Survival Varies by Mutational Signature
Survival outcomes in metastatic invasive lobular carcinoma (ILC) differ based on specific mutational signatures, impacting treatment stratification.
T-DXd Side Effects in Breast Cancer Warrant Continued Attention
Clinicians must maintain vigilance for adverse events associated with trastuzumab deruxtecan (T-DXd) in breast cancer, particularly interstitial lung disease.
Comprehensive Care Improves Outcomes for CAYA Cancer Survivors
Comprehensive, multidisciplinary care models are essential for childhood, adolescent, and young adult (CAYA) cancer survivors to mitigate long-term sequelae.
More Breast Cancer Patients Can Skip Axillary Dissection
New data presented at ASCO 2026 indicates an expanded cohort of breast cancer patients can safely omit axillary lymph node dissection.
HER2-Expressing Breast Cancer: Advancements in Targeted Therapies
New therapeutic strategies for HER2-expressing breast cancer presented at ASCO 2026 demonstrate improved outcomes across disease stages.